NicOx is still in the red, but less. The pharmaceutical company announced on Thursday evening a net loss of 60.4 million euros in 2009, cons -73.9 million euros in 2008.
The operating loss amounted to 62 million euros against 79.2 million last year. Operating expenses were reduced by more than 20 million euros, to 66.7 milllion euros. "The majority of these expenses was related to research and development, including expenses related to the two regulatory submissions for naproxcinod, moderates the group.
Revenues NicOx stands at 1.1 million euros at December 31, 2009 against 3.4 million million a year ago.No revenue was recognized during the last quarter of 2009, NicOx said in a statement.
Finally, NicOx closing the year with cash of 148.3 million euros, up 42% through a capital increase generated net total proceeds of $ 94.6 million at the end of year.
NicOx provides no forecast for 2010 but says he will continue to spend this year preparing for the commercialization of Naproxcinod, which he expects to run a turnover of over one billion euros Payday Advance .
The company announced Wednesday it had granted Bausch & Lomb the exclusive worldwide rights of NCX 116, treatment of glaucoma and ocular hypertension, for a total of up to $ 169.5 million.
In exchange, investors reacted immediately: the NicOx shares rose almost 6%. Rebelotte Thursday with unehausse of 5.7%. Thus, actions cotent at closing 5.92 euros. The bar is close to EUR 6.
However, the exchange price is still below its levels there are still four months (the title was worth ? 7.9) or June 2009 (it was over 10 euros) … or all of its first steps on the Paris stock exchange (the record stands at 39 euros). It was late 1999.
ALSO READ:
"NicOx: the title takes off after the signing of an agreement
- The Paris Bourse gained more than 3% above the 3600 points
- Paris should take its first steps into the red
- Wall Street expected from equilibrium
- Prudence CAC 40 before U.S. jobs
- Sales of Zodiac unscrew